The Corporate Press Release Ledger tracks 8-K Regulation FD and Item 7.01 and 8.01 press-release filings with extracted exhibit titles, detected wire services and topic families, drawn from public SEC EDGAR data over a rolling window and refreshed daily. Every entry links the official filing; topics are derived labels, not issuer claims.
U.S. FDA Approves Ziihera ® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma